중추신경계 치료제 시장 : 시장 예측(2026-2032년)

The Central Nervous System Therapeutics Market is projected to grow by USD 253.54 billion at a CAGR of 7.54% by 2032.

Central nervous system therapeutics encompass medicines and advanced treatment approaches for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, migraine, depression, schizophrenia, anxiety disorders, neuropathic pain, and rare neurogenetic conditions. The field is being reshaped by the rising burden of neurological disorders, aging populations, improved diagnostic capabilities, expanded mental health awareness, and accelerated innovation in precision neurology, neuroimmunology, and neuropsychiatry. Data from global health authorities consistently identify neurological conditions as a leading contributor to disability and ill health worldwide, while dementia, stroke-related impairment, epilepsy, migraine, and mood disorders continue to create substantial clinical and socioeconomic pressure on healthcare systems. At the same time, central nervous system drug development remains scientifically complex due to blood-brain barrier challenges, heterogeneous disease biology, long trial durations, high placebo response in psychiatric studies, and the need for sensitive biomarkers. Industry priorities are shifting toward disease-modifying therapies, earlier intervention, patient stratification, digital endpoints, real-world evidence, and integrated care pathways that connect diagnosis, treatment adherence, rehabilitation, caregiver support, and long-term monitoring. For stakeholders across pharmaceutical development, biotechnology, clinical research, payer strategy, and healthcare delivery, the central nervous system therapeutics landscape requires a disciplined focus on validated mechanisms, meaningful clinical outcomes, regulatory alignment, and equitable patient access.

Transformative Shifts in the CNS Therapeutics Landscape

The central nervous system therapeutics landscape is undergoing transformative shifts as treatment development moves beyond symptomatic relief toward targeted, biology-led intervention. In neurodegenerative diseases, advances in amyloid, tau, alpha-synuclein, neuroinflammation, lysosomal function, mitochondrial biology, and genetic risk pathways are enabling more focused clinical programs, while the adoption of cerebrospinal fluid assays, neuroimaging, electroencephalography, and blood-based biomarkers is improving patient selection and disease staging. In psychiatry, innovation is expanding beyond traditional monoamine-based approaches to include glutamatergic modulation, neuroplasticity pathways, circadian biology, inflammation-linked mechanisms, and rapid-acting therapies for treatment-resistant conditions. The epilepsy and migraine treatment areas illustrate how mechanism-based development can improve outcomes through more precise targeting of ion channels, neuropeptides, and synaptic signaling. Regulatory expectations are also evolving, with greater emphasis on clinically meaningful endpoints, validated biomarker use, long-term safety monitoring, post-authorization evidence, and inclusion of diverse patient populations. Healthcare delivery is shifting toward multidisciplinary models that integrate neurologists, psychiatrists, primary care providers, caregivers, rehabilitation specialists, and digital monitoring tools. These changes are elevating the importance of evidence generation across the full product lifecycle, from translational science and adaptive clinical trial design to pharmacovigilance, adherence support, and health technology assessment.

Cumulative Impact of Artificial Intelligence in CNS Therapeutics

Artificial intelligence is creating cumulative impact across central nervous system therapeutics by improving how researchers discover targets, classify patients, design trials, and monitor outcomes. In discovery, machine learning models are being applied to genomics, proteomics, transcriptomics, imaging, electrophysiology, and clinical datasets to identify disease-relevant pathways and predict compound properties, including central nervous system penetration and toxicity risk. In clinical development, artificial intelligence supports protocol optimization, site selection, eligibility screening, synthetic control exploration where appropriate, and detection of patient subgroups with distinct progression patterns. Natural language processing can help structure clinical notes and patient-reported information, while computer vision and signal analytics are expanding the utility of magnetic resonance imaging, positron emission tomography, electroencephalography, speech analysis, gait analysis, sleep data, and wearable-derived digital biomarkers. These capabilities are particularly relevant in Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, depression, and neurodevelopmental conditions, where disease trajectories are heterogeneous and conventional endpoints may be slow to change. However, artificial intelligence adoption in CNS therapeutics must be governed by data quality, transparency, bias mitigation, privacy protection, regulatory validation, and clinical interpretability. The strongest applications are those that complement expert clinical judgment, improve reproducibility, and generate evidence that can withstand scientific, regulatory, and payer scrutiny.

Key Regional Insights Across CNS Therapeutics

Asia-Pacific is becoming increasingly important in central nervous system therapeutics as aging demographics, expanding specialist capacity, and growing recognition of mental health and neurodegenerative disease burden drive demand for improved diagnosis and treatment access. Countries across the region are investing in hospital infrastructure, clinical research networks, dementia strategies, and digital health platforms, although access remains uneven between major urban centers and rural populations. Europe benefits from coordinated regulatory systems, national health technology assessment processes, strong academic neuroscience networks, and increasing policy attention to dementia, mental health, multiple sclerosis, epilepsy, and rare neurological conditions. North America remains a highly advanced environment for CNS therapeutic innovation, supported by established neuroscience research institutions, clinical trial infrastructure, specialty care networks, patient advocacy activity, and regulatory pathways that encourage evidence-based development in areas of high unmet need. Africa faces significant unmet need in neurological and psychiatric care due to limited specialist density, diagnostic gaps, medicine availability constraints, conflict-related mental health needs, and stigma, yet opportunities are emerging through telemedicine, essential medicines programs, epilepsy initiatives, workforce training, and broader integration of mental health into primary care. Latin America presents a complex CNS care environment shaped by expanding public health coverage, increasing neurological disease recognition, and persistent disparities in specialist availability, diagnostic imaging, rehabilitation services, and access to newer medicines. The Middle East is strengthening CNS care through investments in tertiary hospitals, medical tourism hubs, digital health systems, and national health transformation programs, while still addressing workforce development, continuity-of-care challenges, and access variation across income groups and geographies.

Key Group Insights for CNS Therapeutics

NATO member countries overlap with many high-capacity healthcare systems and are increasingly attentive to brain health, traumatic brain injury, post-traumatic stress disorder, neurorehabilitation, and mental health resilience, particularly for active-duty personnel, veterans, emergency responders, and civilian populations exposed to crisis-related stressors. The G7 remains influential in shaping CNS therapeutic standards through advanced research funding, regulatory science, real-world evidence generation, rare disease frameworks, aging policy, and adoption of precision medicine approaches in neurology and psychiatry. The European Union provides a structured environment for CNS therapeutics through harmonized medicines regulation, cross-border research collaboration, pharmacovigilance systems, European reference networks, and health technology assessment frameworks that emphasize comparative clinical benefit, safety, and cost-effectiveness. BRICS countries collectively represent diverse CNS treatment environments, with large patient populations, expanding clinical trial capacity, growing domestic pharmaceutical capabilities, and significant variation in reimbursement, urban-rural access, specialist distribution, and diagnostic infrastructure. ASEAN countries are expanding central nervous system therapeutic access through healthcare modernization, broader insurance coverage, regional regulatory cooperation, and growing attention to stroke, epilepsy, dementia, depression, and neurodevelopmental disorders, although affordability and specialist shortages remain important constraints. The GCC is advancing CNS care through high-investment health systems, tertiary neurology centers, digital health adoption, national strategies focused on chronic disease management, mental health, and specialized rehabilitation, and growing attention to neurological complications associated with aging and metabolic disease. Across these groups, policy alignment, data interoperability, workforce expansion, evidence-based reimbursement, and equitable access are central to improving CNS treatment outcomes.

Key Country Insights in CNS Therapeutics

The United States is a leading center for central nervous system therapeutic research, specialty care delivery, advanced diagnostics, and patient advocacy, with strong activity in neurodegenerative disease, psychiatry, epilepsy, migraine, multiple sclerosis, and rare neurological disorders. China is rapidly expanding CNS research capacity, hospital-based neurology services, and diagnostic adoption, driven by aging demographics, stroke burden, dementia recognition, and mental health reform. Germany is characterized by advanced hospital infrastructure, specialty neurology services, clinical research strength, and rigorous reimbursement assessment, supporting evidence-based adoption of CNS therapeutics. Japan has deep expertise in aging-related neurological disease, dementia care, Parkinson's disease, and advanced diagnostics, supported by a rapidly aging population and established specialist infrastructure. India faces a high burden of epilepsy, stroke-related disability, neuroinfections, dementia, migraine, and psychiatric disorders, with major opportunities in affordable treatment, tele-neurology, digital mental health, and primary-care integration. The United Kingdom maintains a strong neuroscience ecosystem supported by national clinical guidelines, academic research, health data assets, and digital health initiatives, with policy attention to dementia, depression, and severe mental illness. France has established neurological care networks and strong public health engagement in neurodegenerative and psychiatric disorders, while Canada combines publicly funded healthcare access with active neuroscience research and growing emphasis on dementia strategies, mental health services, and indigenous health equity. Australia emphasizes guideline-based CNS care, mental health policy, digital health access, and neurological rehabilitation, while Italy and Spain continue to strengthen dementia care, multiple sclerosis services, epilepsy management, and mental health integration within regional health systems. South Korea is advancing neuroscience research, hospital technology, dementia policy, and digital therapeutics integration, supported by strong health information infrastructure. Russia has significant CNS treatment needs across neurology and psychiatry, with access shaped by regional infrastructure, workforce distribution, and domestic healthcare priorities. Brazil has substantial demand for CNS therapies due to population scale, aging, epilepsy prevalence, mental health needs, and expanding public and private care pathways, though regional access differences remain significant. Mexico is expanding neurological and psychiatric care capacity, while disparities in specialist access, diagnostic availability, and reimbursement influence adoption of newer CNS treatments.

Actionable Recommendations for CNS Therapeutics Leaders

Industry leaders in central nervous system therapeutics should prioritize biologically validated targets, patient stratification strategies, and biomarker-enabled development plans to improve the probability of clinically meaningful outcomes. Clinical programs should incorporate diverse patient populations, pragmatic endpoint selection, caregiver-relevant outcomes, functional measures, safety surveillance, and real-world evidence planning from early development onward. Organizations should invest in translational neuroscience capabilities that connect molecular biology, imaging, electrophysiology, digital biomarkers, and longitudinal clinical datasets. Partnerships with academic centers, hospitals, patient organizations, and technology providers can strengthen recruitment, adherence, data quality, trial diversity, and post-approval evidence generation without compromising scientific rigor. Access strategies should be designed early, with clear articulation of clinical value, safety monitoring requirements, administration logistics, diagnostic prerequisites, and health system impact. For neurodegenerative and rare neurological diseases, stakeholders should prepare for earlier diagnosis pathways and the infrastructure required for biomarker testing, infusion or specialty administration, genetic counseling where appropriate, and long-term monitoring. In psychiatry, leaders should address adherence, comorbidity, stigma, relapse prevention, and care continuity as core components of therapeutic success. Across all CNS categories, responsible artificial intelligence governance, cybersecurity, regulatory compliance, and transparent model validation should be embedded in operating models. Sustainable progress will depend on aligning innovation with measurable patient benefit, affordability, provider readiness, and equitable access.

Research Methodology for CNS Therapeutics Analysis

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and evidence-based sources relevant to central nervous system therapeutics. The research approach includes review of peer-reviewed medical literature, clinical practice guidelines, regulatory publications, public health databases, disease burden assessments, clinical trial registries, pharmacovigilance resources, health technology assessment documents, and policy publications from recognized health authorities. Disease-area evaluation covers neurology, psychiatry, neuroimmunology, neurodegeneration, pain medicine, epilepsy, movement disorders, neurodevelopmental disorders, and rare CNS conditions. Regional and country-level insights are synthesized by examining healthcare infrastructure, diagnostic capacity, specialist access, reimbursement frameworks, demographic trends, research activity, and public health priorities. The methodology emphasizes triangulation across credible sources to avoid reliance on single-point claims and excludes unsupported projections, market sizing, market share, and commercial forecasting. Qualitative analysis is applied to identify recurring themes such as biomarker adoption, artificial intelligence use, clinical trial modernization, regulatory expectations, access disparities, and integrated care models. Findings are interpreted through a healthcare industry lens to support strategic decision-making while maintaining factual accuracy, neutrality, and relevance for stakeholders in CNS drug development, medical affairs, health policy, and care delivery.

Conclusion: Future Direction of CNS Therapeutics

Central nervous system therapeutics are entering a pivotal period defined by scientific progress, unmet patient need, and increasing pressure to demonstrate meaningful clinical value. Advances in biomarkers, genomics, imaging, digital measurement, neuroimmunology, and artificial intelligence are improving the ability to identify disease mechanisms, select appropriate patients, and monitor therapeutic response. At the same time, the field continues to face persistent challenges, including complex disease biology, high development risk, variable treatment access, stigma surrounding mental health, limited specialist availability, and uneven diagnostic infrastructure in many regions. Regional, group, and country-level differences show that CNS therapeutic success depends not only on innovation but also on diagnostic capacity, reimbursement readiness, workforce development, evidence standards, and patient-centered delivery models. Stakeholders that integrate rigorous neuroscience, responsible data science, inclusive clinical research, and equitable access planning will be better positioned to address neurological and psychiatric disease burden. The future of CNS therapeutics will be shaped by therapies that can prove durable benefit, fit real-world care pathways, and improve outcomes for patients, caregivers, clinicians, and healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Central Nervous System Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Antidepressants
• 7.3. Antipsychotics
• 7.4. Anticonvulsants
• 7.5. Anxiolytics
• 7.6. Anesthetics
• 7.7. Pain Relievers
• 7.8. CNS Stimulants

8. Central Nervous System Therapeutics Market, by Disease Indication

• 8.1. Introduction
• 8.2. Neurodegenerative Disorders
  • 8.2.1. Alzheimer's Disease
  • 8.2.2. Parkinson's Disease
  • 8.2.3. Huntington's Disease
  • 8.2.4. Multiple Sclerosis
• 8.3. Psychiatric Disorders
  • 8.3.1. Major Depressive Disorder
  • 8.3.2. Anxiety Disorders
  • 8.3.3. Schizophrenia
  • 8.3.4. Bipolar Disorder
• 8.4. Neurovascular Diseases
  • 8.4.1. Stroke
  • 8.4.2. Cerebral Aneurysm
• 8.5. CNS Trauma
  • 8.5.1. Traumatic Brain Injury (TBI)
  • 8.5.2. Spinal Cord Injury

9. Central Nervous System Therapeutics Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Injectable
• 9.3. Oral
• 9.4. Transdermal

10. Central Nervous System Therapeutics Market, by Mechanism Of Action

• 10.1. Introduction
• 10.2. Gene Therapy
• 10.3. Monoclonal Antibodies
• 10.4. Peptides
• 10.5. Small Molecules

11. Central Nervous System Therapeutics Market, by End User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Home Care
• 11.4. Hospitals

12. Central Nervous System Therapeutics Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline Pharmacies
• 12.3. Online Pharmacies

13. Central Nervous System Therapeutics Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Africa
• 13.5. Latin America
• 13.6. Middle East

14. Central Nervous System Therapeutics Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. European Union
• 14.4. BRICS
• 14.5. ASEAN
• 14.6. GCC

15. Central Nervous System Therapeutics Market, by Country

• 15.1. United States
• 15.2. China
• 15.3. Germany
• 15.4. Japan
• 15.5. India
• 15.6. United Kingdom
• 15.7. France
• 15.8. Canada
• 15.9. Australia
• 15.10. Italy
• 15.11. South Korea
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. AC Immune SA
• 17.3. Acadia Pharmaceuticals, Inc.
• 17.4. Alkermes plc
• 17.5. Amgen Inc.
• 17.6. Anavex Life Sciences Corp.
• 17.7. Biogen Inc.
• 17.8. Bristol-Myers Squibb Company
• 17.9. Eli Lilly and Company
• 17.10. F. Hoffmann-La Roche Ltd.
• 17.11. GSK plc
• 17.12. H. Lundbeck A/S
• 17.13. Ipsen S.A.
• 17.14. Jazz Pharmaceuticals plc
• 17.15. Johnson & Johnson
• 17.16. Merck & Co., Inc.
• 17.17. Neumora Therapeutics, Inc.
• 17.18. Neurocrine Biosciences, Inc.
• 17.19. Neurona Therapeutics Inc.
• 17.20. Novartis AG
• 17.21. Otsuka Pharmaceutical Co., Ltd.
• 17.22. Pfizer Inc.
• 17.23. PTC Therapeutics, Inc.
• 17.24. Sanofi S.A.
• 17.25. Sumitomo Pharma Co., Ltd.
• 17.26. Supernus Pharmaceuticals, Inc.
• 17.27. Takeda Pharmaceutical Company Limited
• 17.28. Teva Pharmaceutical Industries Ltd.
• 17.29. UCB S.A.
• 17.30. Viatris Inc.